Rosuvastatin Attenuates Inflammation and Oxidative Stress in Deep Vein Thrombosis Rats via the TLR4/TRAF6/NF-κB Pathway: An Experimental Animal Study

Deep vein thrombosis is a dangerous condition where a blood clot forms in the deep veins, usually in the legs. While doctors have long treated this by using blood thinners to stop the clot from growing, these medicines do not fix the underlying trouble that caused the clot in the first place. That trouble is often a storm of inflammation and oxidative stress inside the body. Inflammation is the immune system's response to injury, but when it goes on too long, it damages blood vessels. Oxidative stress is a similar kind of damage caused by unstable molecules that attack healthy cells. These two problems feed each other, creating a cycle that makes clots more likely to form and harder to break down. For patients who cannot take standard blood thinners because of bleeding risks, finding a way to calm this internal storm without thinning the blood further is a major medical goal.

Researchers at Inner Mongolia Medical University and Chifeng Municipal Hospital set out to see if a common cholesterol-lowering drug called rosuvastatin could do more than just lower fat levels. They wanted to know if this drug could stop the inflammation and oxidative stress that drive deep vein thrombosis. To find out, they created a model of the disease in rats by surgically blocking a major vein in the lower body, which caused blood clots to form naturally. They then divided the animals into groups, giving some of them different amounts of rosuvastatin for two weeks. One group received a standard blood thinner for comparison, while another group received the drug along with a substance known to trigger the immune system, just to see if the drug's effects could be undone.

The results showed that the rats with the blocked veins suffered from a severe imbalance. Their blood clotted much faster than normal, their bodies were flooded with inflammatory signals, and their natural defenses against oxidative damage were nearly exhausted. However, the rats treated with rosuvastatin showed a clear, dose-dependent improvement. The higher the dose of the drug, the better the outcome. The animals receiving the highest dose of rosuvastatin saw their blood clotting times return to near-normal levels, their levels of fibrinogen—a protein that helps blood clot—drop significantly, and their inflammatory markers decrease dramatically. The drug also restored the activity of the body's own antioxidant enzymes, which had been suppressed by the disease, and reduced the amount of fatty damage in their tissues.

To prove exactly how the drug was working, the researchers used a specific test. They gave a group of rats the medium dose of rosuvastatin along with a substance that activates a specific immune pathway called TLR4. This pathway acts like a master switch for inflammation. When they turned this switch on, the beneficial effects of the drug vanished. The rats' blood clotting times shortened again, inflammation surged back, and antioxidant levels fell. This reversal confirmed that rosuvastatin works by blocking this specific TLR4 pathway. Without this blockage, the drug could not calm the storm or protect the blood vessels. The study found that the drug's ability to reduce inflammation was almost entirely dependent on this mechanism, while its effect on blood clotting was also linked to it, though perhaps through a slightly more complex set of interactions.

The findings suggest that rosuvastatin offers a multi-targeted approach to treating deep vein thrombosis. Instead of just slowing down the clotting process like traditional blood thinners, the drug appears to calm the internal fire that makes clots form in the first place. By stopping the TLR4 pathway, it breaks the cycle where inflammation leads to more oxidative stress, which in turn leads to more inflammation. While the study was conducted in rats and requires further testing in humans, it points to a potential new strategy for patients who cannot tolerate standard anticoagulants. For these individuals, a drug that treats the root cause of the clotting disorder without increasing the risk of bleeding could be a vital alternative. The research provides a clear experimental basis for the idea that managing the body's inflammatory response is just as important as managing the blood itself when treating this dangerous condition.